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Abstract  
The brainstem-derived neuropeptide S (NPS) has a multidirectional regulatory activity, 
especially  as a potent anxiolytic factor. Accumulating data suggests that neuroleptics affect 
peptidergic signaling in  various brain structures. However, there is no information regarding 
the influence of haloperidol on NPS and NPS receptor (NPSR) expression. We assessed NPS 
and NPSR mRNA levels in brains of rats treated with haloperidol using quantitative Real-
Time PCR. Chronic haloperidol treatment (4 weeks) led to a striking upregulation of NPS and 
NPSR expression in the rat brainstem. Conversely, the NPSR mRNA expression was 
decreased in the hippocampus and striatum. This stark increase of NPS in response to 
haloperidol treatment supports the hypothesis that this neuropeptide is involved in the 
dopamine-dependent anxiolytic actions of neuroleptics and possibly also in the 
pathophysiology of mental disorders.  Furthermore, our findings  underline the complex 
nature of potential interactions between dopamine receptors and brain peptidergic pathways, 
which has potential clinical applications. 
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Significant outcomes    
- For the first time, we assessed the influence of haloperidol on NPS/NPSR mRNA 
expression in the rat brain 
- We proved a significant upregulation of NPS mRNA level  in the rat brainstem after 
haloperidol administration 
Limitations: 
- We assessed only mRNA expression , protein level was not measured 




Neuropeptide S (NPS) is a selective 20-amino acid ligand for the NPS receptor 
(NPSR), a Gs and Gq – coupled receptor formerly identified as orphan receptor GPR 154 (1). 
NPS is an endogenous modulator of a wide spectrum of physiological activities in the brain. It 
exerts anxiolytic effects, stabilizes arousal state, regulates food intake  as well as plays a role 
in the pathomechanism of fear modulation and addiction (2-8). In the rat brain, expression of 
NPS is shown almost exclusively within the locus coeruleus, principal trigeminal nucleus and 
lateral parabrachial nucleus, whereas in mouse NPS expression in the Kölliker-Fuse nucleus 
has also been reported (9). In contrast to the specific expression of NPS, NPSR mRNA is 
abundant within the brain and has been detected in the olfactory bulb, piriform cortex, 
amygdala, hypothalamus, thalamus and brainstem (10). Receptor stimulation leads both to a 
release of Ca
2+
 reserves to the neuroplasm and to an increase of cAMP levels (11,1). From a 
neuropsychiatric viewpoint, the most important role of NPS seems to be its activity at the 
level of neuronal pathways related to the neurobiology of fear (12). A number of behavioral 
tests prove that central or even intranasal NPS administration has a strong anxiolytic effect in 
rats, which may be related to an increase of dopamine release in the medial prefrontal cortex 
(13,14). The stimulatory effect of NPS on dopaminergic signaling suggests that this 
neuropeptide might increase dopamine synthesis and/or its turnover within the synaptic cleft 
(14). Moreover, NPS application to organotypic hippocampal slices activated synaptic 
plasticity in CA1 and CA3 areas, whereas targeted NPS microinjection directly to the ventral 
CA1 was enough to reduce fear related behaviour in mice (15). Furthermore,  under in vitro 
conditions NPS, acting through its receptor, weakens the neural activity stream from the 
dentate gyrus to the CA1 area (15). NPS peptide administration into the mouse amygdala 
results in conditioned fear elimination, but it has no effect before the conditioning process 
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(16). Recent experiments on healthy individuals also suggest, that NPSR gene T-alleles could 
be connected with fear, excessive stress reaction and increased HPA axis stimulation (5). 
Moreover, NPSR1 gene variation affects the glutamate/glutamine (Glx) levels in the rat 
cingulate cortex during induced panic attacks (17). Studies by Zhang et al. (18) prove that 
NPS expression in the locus coeruleus and a decrease of NPSR internalization level in the 
limbic system coexist with chronic pain and anxiety (24). On the other hand, NPS can 
stimulate inhibitory GABAergic transmission in the rat medial amygdala, reducing fear 
related responses (16). The NPS signaling  may be also involved in the regulation of HPA 
axis acting as a part of negative feedback loop in the response to various stress stimuli (4). 
Another clinically intriguing report has associated NPSR polymorphisms with 
neuropsychiatric disorders including schizophrenia (19). Noteworthy, anxiety  is considered 
as an important and relatively frequent symptom of schizophrenia, which is significantly 
connected with an elevated risk of severe consequences including suicidal behaviour (20). 
Post-traumatic stress disorder (PTSD) and obsessive compulsive disorder (OCD) are present 
in 38.3% of patients suffering from schizophrenia (21). Interestingly, some recent findings 
suggest a role of the NPS signaling in the regulation of motor functions at the level of basal 
ganglia (22,23).  
Haloperidol, a classical but still widely administered D2 receptor antagonist effectively 
reduces the psychosis suggesting impaired dopaminergic signaling as a key mechanism of 
positive schizophrenia symptoms (24). Noteworthy, haloperidol is a non-specific neuroleptic 
with affinity to numerous receptors, including dopamine D2, serotonin 5-HT2, -adrenergic 
and -opioid receptors (25-27). Haloperidol shows either potentially beneficial anxiolytic and 
sedative properties or a wide spectrum of unfavorable side effects including tardive 
dyskinesia, neuroleptic malignant syndrome, akathisia and QT-interval prolongation (28-30). 
Nevertheless, the neurochemical mechanism of anxiolytic and dyskinetic actions of 
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neuroleptics, both classical and atypical, is so far poorly understood. Some reports show that 
atypical antipsychotics, but not haloperidol can upregulate the level of steroid GABAA 
receptor stimulators in the rat brain (31). In turn, the blockage of serotonin 5-HT2 receptors 
with haloperidol may be responsible for its anxiolytic effect (32). Hypothetically, the 




Aims of the Study 
 
Accumulating but still limited findings suggest that neuroleptics may affect peptidergic 
regulatory pathways in various brain structures. For example, both chlorpromazine and 
clozapine affect corticotropin-releasing hormone (CRH) expression probably via activation of 
the PI3K/Akt signalling cascade, however PKC-related pathway may be also involved (33). 
Haloperidol stimulates CRH mRNA expression and also increases  the gonadotropin-releasing 
hormone (GnRH) secretion in the rat hypothalamus (34). In turn, both quetiapine and 
olanzapine are able to inhibit  the release of CRH from isolated rat hypothalami and 
hippocampi (35).  Haloperidol upregulates neurotensin levels in the rat striatum, hippocampus 
and the frontal cortex, but  risperidone  decreases  the peptide expression  (36). Conversely, 
long-term treatment with haloperidol decreases NPY mRNA levels in the rat amygdala and 
hippocampus, while olanzapine and clozapine show the same effect in the striatum, nucleus 
accumbens and anterior cingulated cortex (37). Long-term treatment with risperidone also 
downregulates the NPY mRNA expression in the rat hypothalamus (38). In contrast, a 
stimulatory effect of subchronically administered olanzapine on NPY expression is also 
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suggested (39). Olanzapine increases  calcitonin gene-related peptide (CGRP) 
immunoreactivity in the rat brain (40).  
Despite these ongoing studies, almost no data exists regarding the interaction of  
neuroleptics with brain NPS signalling. We therefore examined the effect of administration of  
haloperidol, a classical butyrophenone type antipsychotic drug, on NPS and NPSR expression 
in the rat brain and showed a robust significant increase in brainstem NPS mRNA expression 
as a result of chronic drug administration.  
 




The experiments  were performed on adult male Sprague-Dawley rats (2-3 months old, 
180-210 g). We injected two groups of animals (n=4) with either control vehicle (saline) or 
haloperidol (2 mg/kg/day) every day for 4 weeks (28 injections per rat). All procedures were 
conducted  in a manner consistent  with  NIH  Guidelines for Care and Use of Laboratory 
Animals and approved by the Local Bioethical Committee at the Medical University of Silesia 
(agreement no. 36/2012). 
 
Material collection and reverse transcription 
   
24 hours after the last drug administration, animals were anaesthetized with isoflurane. 
Then,  the brains were quickly removed and we performed microsurgical excision of samples 
from  hypothalamus, hippocampus, striatum and brainstem. After that, all samples were 
homogenized with an ultrasound homogenizer (Heildolph DIAX 900, Germany) in 1 ml of 
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TRIzol® Reagent (Life Technologies) and total mRNA was extracted and dissolved in 50 μl 
of RNAse-free water.  Transcription of mRNA into cDNA  was performed by incubation in 
buffered solution of reverse transcriptase MMLV-RT with RNAsin, oligo-dT and a mix of 
nucleotides at 42 
0
C for 60 min using a DNA Thermal Cycler 480 (Perkin Elmer Inc., 
Waltham, MA). Initial mRNA solutions contained  5µg of RNA per 100 µl. 
 
Quantitative real-time PCR 
 
 We performed quantitative Real-Time PCR reaction (qPCR) with the use of FastStart 
SYBR Green Master Mix (Roche) in a Light Cycler ® 96 (Roche) for 45 rounds. Expression 
levels of NPS and NPSR were compared with expression of housekeeping gene 
glyceraldehyde phosphate dehydrogenase (GAPDH). cDNA amplification was performed 
using the following primers: for NPS; Forward: 5’ - TTGGAGTTATCCGGTCCTCTCTT -
3’,    Reverse: 5’-TTGGAGTTATCCGGTCCTCTCTT-3’, for NPSR; Forward: 5’- 
TGCAAGGTGCAAAGATCCCA-3’, Reverse: 5’-AATCTGCATCTCATGCCTCTC-3’, for 





Statistical analysis was done with Statistica (Systat Software). We presented data (on 
graphs) as mean ± SEM. Mean differences between groups of animals were analyzed using 







In the current study, rats treated chronically with haloperidol manifested strongly 
increased relative NPS mRNA expression in the brainstem;  128,75 ± 6,48 versus control: 
1,08 ± 0,33 (p = 0,000246). Although, there is an unexpectedly massive (about 120-fold) 
increase of NPS mRNA level in this region we excluded the effect of haloperidol on GAPDH 
expression, as mean Cq values for this gene are very similar for control animals (15,65) and 
for haloperidol treated animals (15,48). We have also found a trend for decreased NPS mRNA 
level in the hypothalamus: 13,79 ± 0,36 versus control: 15,59 ± 4,09, nevertheless this change 
was not statistically significant (Fig.1). The NPS mRNA expression in the hippocampus and 
striatum was undetected. After long-term administration of haloperidol NPSR mRNA 
expression was downregulated in the hippocampus; 5, 6 ± 4,03 versus control: 15,76 ± 3,86 
and striatum: 9,78 ± 2,42 versus control: 21,19 ± 8,67, unchanged in the hypothalamus 20,17 
± 0,81 versus control: 24,01 ± 2,65 and highly increased in the brainstem: 60,36 ± 10,48 




At present, there are relatively few reports concerning NPS expression changes related 
to antipsychotic drug activity. Studies on the influence of this group of pharmaceuticals on 
peptidergic regulatory pathways could be a source of hypothesis explaining alternative ways 
of their pharmacological effects. In our analysis we focused on the expression of the NPS and 
NPSR mRNA in selected brain structures of rats chronically treated with haloperidol. The 
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results indicate that chronical drug administration may modulate the expression of NPS and 
NPSR mRNAs in selected rat brain regions. 
The statistically significant elevation of the brainstem NPS mRNA level, after long-
term haloperidol administration stays in agreement with our recent results showing that short 
and chronical treatment with the neuroleptics chlorpromazine and olanzapine increased the 
NPS mRNA expression in the rat hypothalamus (41). In addition, haloperidol stimulates the 
secretion of gonadotropin-releasing hormone (GnRH) (34) and increases  corticotrophin-
releasing hormone (CRF) mRNA expression in the rat hypothalamus (42). On the other hand, 
haloperidol, but not risperidone, elevates neurotensin levels in the rat striatum, hippocampus 
and  frontal cortex. Conversely, in the occipital cortex, risperidone, but not haloperidol, 
reduces neurotensin expression (36). In contrast, long-term haloperidol 
administration decreases NPY mRNA expression in the rat amygdala and hippocampus while 
olanzapine and clozapine show the same effect in the nucleus accumbens, striatum and 
anterior cingulated cortex (18.). Similarly, chronically administered risperidone decreases the 
NPY mRNA level in the rat hypothalamus (38).  Only olanzapine significantly decreases the 
NPY mRNA level in the lateral septal nucleus (37). A decrease in the hypothalamic NUCB2 
and nesfatin-1 expression after chronical haloperidol administration was also recently 
reported (43). In our experiment, the NPS mRNA expression remains unchanged in 
hypothalamus after drug treatment. This result is in line with the study showing that 
hypothalamic NPY mRNA level did not change after long-term neuroleptic administration to 
rats (43). 
Furthermore, it is suggested, that haloperidol can induce disturbances in the oxidative-
antioxidative balance. It should be noted that the elevation of NPS expression observed in our 
study may be a part of neuronal protective mechanism against an extended treatment with this 
drug. Moreover, it was shown, that NPS can weaken lipid peroxidation processes in the 
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mouse brain cortex, which confirms its neuroprotective activity during the occurrence of 
oxidative stress (44).  
Single dose treatment with haloperidol and other typical antipsychotics may increase 
the number of spontaneously active dopaminergic cells in the rat brainstem (areas A9 and 
A10) whereas olanzapine and atypical neuroleptics stimulate cell populations  in  A10, but not 
A9 (45). The long-term treatment with neuroleptics proved that multiple haloperidol 
administration can lead to a decrease of the number of spontaneously active cells in A9 and 
A10 areas of the brainstem (46) whereas Stockton and Rasmussen (47) showed that chronic 
exposition to olanzapine results in a decreased number of active neurons in A10, but not in A9 
area.  
Interestingly, after long-term treatment with haloperidol, the NPSR mRNA levels were 
downregulated both in the hippocampus and striatum. This result is consistent with our recent 
finding that NPSR mRNA levels in the same structures were decreased after chronical 
chlorpromazine and olanzapine administration. Additionally, both short and long-term 
exposition to chlorpromazine decreased the NPS mRNA level in the hypothalamus (41). 
Presented phenomena are rather difficult to interpret without specific analysis of potential 
interactions between NPSR mode of action and dopaminergic signaling. Possibly, haloperidol 
may modulate the NPS-related synaptic plasticity in the hippocampus mediating any kinds of 
fear responses (15).  Probably, the high elevation of NPS mRNA level in brainstem neurons 
may suggest an increased neuropeptide synthesis and release to the hippocampal formation 
and striatum. Thus, it should be taken into consideration that a decrease in NPSR mRNA 
expression could be a compensatory response to increased NPS concentration in these 
structures. In contrast, the NPSR mRNA level in brainstem was distinctly elevated  after 
chronical haloperidol administration. Theoretically, this neuroleptic could increase the 
sensitivity and/or activity of NPS signaling in the brainstem and in consequence facilitate 
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anxiolytic mechanisms. Importantly, the brainstem contains a distinct population of aminergic 
NPSR-expressing neurons (10) that play numerous central roles such as modulation of 
cortical glutamatergic transmission and maintaining the arousal state. We therefore can 
hypothesize that haloperidol may affect them indirectly via stimulation of NPS pathway. 
Chronic administration of haloperidol evokes several considerable side effects including 
prolonged sedation and tardive dyskinesia besides other motor disabilities.  
Recent data suggested the role of NPS in locomotion and related these actions with 
dopaminergic signaling (44). It was shown that intracerebroventricular infusion of NPS to the 
striatum and substantia nigra increase the locomotor activity in rats. This effect is 
counteracted both by SHA 68 (a selective antagonist of NSPR) and antalarmin (a CRF-1 
receptor blocker) suggesting that CRF plays a significant role in the NPS-related control of 
locomotion activity (23). Similarly, central injection of NPS abolished motor impairments 
evoked by dopaminergic neurotoxin 6-OHDA (22). Probably, NPS may stimulate dopamine 
release via selective activation of NPSR receptors in the extrapyramidal system (48). The 
observed downregulation of striatal NPSR mRNA expression suggests that pharmacological 
activity of haloperidol may also manifest at the level of NPS transmission in the basal ganglia, 
which may be one of the alternative ways of triggering dyskinetic side effects by this 
medication. Intriguingly, a recent study reports that haloperidol can also decrease the 
functional connectivity between substantia nigra and cortical motor regions, which may 
reflect motor disabilities (24). 
Taken together, it is possible that dopamine may inhibit the expression of genes 
encoding some neuropeptides including NPS in certain brain regions. Thus, the blockage of 
dopamine receptors performed by haloperidol can result in compensational expression 
increase of the aforementioned proteins. Mechanisms of anxiolytic side effects of 
antipsychotics are not fully clarified, however it is suggested that the blockage of both 
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dopamine D2 and serotonin 5-HT2 receptors may be responsible for the haloperidol anxiolytic 
action (32). Conversely, some reports show that atypical neuroleptics clozapine and 
olanzapine, but not haloperidol can increase the level of endogenous allopregnanolone and 
allotetrahydrodeoxycorticosterone (THDOC), two positive GABAA receptor modulators in 
the rat brain (49,31,50).  
In conclusion, the fact that haloperidol highly affected the level of NPS and NPSR 
mRNA expression in the rat brain supports the hypothesis that NPS plays a role in the 
anxiolytic actions of neuroleptics and possibly also in the pathophysiology of mental 
disorders; for example in the control of negative schizophrenia. It was also shown recently, 
that synthetic NPS is a potent anxiolytic agent, even in rodents with an innate predisposition 
to high anxiety. Thus, it is strongly suggested that NPS may be a promising, potentially 
beneficial medication in the treatment of anxiety disorders especially in patients with the 
high-risk variant (8). Our intriguing initial data requires further basic pharmacological and 
behavioural studies on the wide spectrum of antipsychotic drugs, but nonetheless highlights 
the complex nature of potential interactions between dopamine receptors and brain 
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Fig. 1.  Quantitative PCR results of relative neuropeptide S mRNA expression levels in the rat 
hypothalamus and brainstem (n=4). Data are presented as mean ± SEM. Statistical analysis was 



















Fig. 2.  Quantitative PCR results of relative NPSR mRNA expression levels in the selected rat brain 
regions (n=4). Data are presented as mean ± SEM. Statistical analysis was performed using non-
parametric Kruskal-Wallis test. Differences were considered significant at p ≤ 0,05. (asterisks). 
 
